It was also reported that sitagliptin, another DPP-4 inhibitor, improves histological changes of NAFLD in mice that have dietary obesity with or without diabetes [6, 7]. This evidence concerns the gene DPP4 and metabolic dysfunction-associated steatotic liver disease.